HIV Patient-reported outcome Cancer Inflammatory bowel disease Fecal microbiota Eligibility Alkylating agents Gènes Stricture Intestinal crypts Inflammatory bowel diseases 18 FDG-PET/CT Maintenance therapy Biologics Rituximab Clinical trial Biomarker Colon Gene expression Inclusion Clinical guidelines Colorectal cancer Colibactin and lipids Crohn's disease Neoadjuvant chemotherapy IL23 Inflammatory Bowel Diseases Anti-TNF agents Methylation Colorectal cancer Résistance Patients experience Disability Helicobacter pylori IBD Ulcerative colitis Genes Original Article Clinical Venous thromboembolism Effectiveness T1118 translocation Epigénétiques Resistance MORTALITY Crohn’s disease Bactéries Survival Dysbiose Contraindication Bacteria Drug Colon cancer Cost effectiveness Thérapie ciblée Consensus Safety Microbiota Immune cells Small molecules Anti-TNF Epigenetics Monitoring Therapeutics Screening Tuberculosis Microbiote Vedolizumab Over 80s Disease progression PCR DNA METHYLATION Eradication Gene methylation Parvimonas micra DNA methylation Colectomy Algorithm Inhibitor MALT Upper gastrointestinal tract Endoscopic treatment Ustekinumab Acceptability Méthylation Dysbiosis Surgery Rituximab plus chlorambucil MARKER CARCINOGENESIS Primary sclerosing cholangitis Kidney diseases Cell adhesion COLON-CANCER Tailored therapy RISK Immunosuppressant IL12 Colonic epithelial primary cells MICROBIOTA Disease Progression Heart disease risk factors